BOTHELL, Wash. - Immunome, Inc. (NASDAQ: IMNM), a biotechnology company specializing in targeted cancer therapies, has recently completed patient enrollment for the Phase 3 RINGSIDE study of AL102 for the treatment of desmoid tumors, as announced by Ayala Pharmaceuticals, Inc. (OTCQX: ADXS). The enrollment milestone follows Immunome's asset purchase agreement earlier this month to acquire AL102 and its related drug candidate, AL101, from Ayala. The closing of this transaction is pending customary conditions.
The Chief Medical Officer of Immunome, Dr. Bob Lechleider, expressed satisfaction with the progress of the RINGSIDE trial, highlighting the strong enrollment in the Phase 3 study and noting the promising responses observed during Phase 2. The company anticipates finalizing the acquisition of AL102 in the upcoming quarter or early in the second quarter.
Immunome's approach to cancer therapy development involves targeting underexplored areas with modalities suited to the biology of each target, including immunotherapies, radioligand therapies, and antibody-drug conjugates (ADCs). The company's proprietary memory B cell hybridoma technology is instrumental in rapidly identifying and characterizing novel antibodies and targets.
The press release also included cautionary statements regarding forward-looking information, emphasizing that such statements are not guarantees of future performance and are subject to risks and uncertainties. These could affect the timing and success of the AL102 program and the completion of the transaction with Ayala.
Immunome's forward-looking statements are based on current expectations and are influenced by factors such as potential litigation, business disruptions, regulatory changes, and the competitive landscape. The company's results may also be impacted by its ability to execute its business plan, including the development and commercialization of its pipeline.
The information in this article is based on a press release statement from Immunome, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.